Key Takeaways
- • NewLimit closed a $435 million Series C funding round led by Founders Fund, marking a significant capital infusion for the South San Francisco-based biotechnology company.
- • The round attracted both new institutional investors—including Thrive Capital, Greenoaks, and Quiet Capital—alongside returning backers such as Kleiner Perkins, Abstract, Valor Equity Partners, and Eli Lilly Ventures.
- • The funding syndicate demonstrates strong institutional confidence in NewLimit's biotechnology platform, with participation from leading venture firms and strategic corporate investors in the life sciences sector.
Summary
NewLimit, a biotechnology company based in South San Francisco, has successfully closed a $435 million Series C funding round, according to the company announcement. The round was led by Founders Fund, one of the prominent venture capital firms focused on deep technology and science-based companies.
The funding syndicate reflects broad institutional confidence in NewLimit's business model and technology. Beyond lead investor Founders Fund, the round included new investors Thrive Capital, Greenoaks, and Quiet Capital. Returning investors participating in the round include Kleiner Perkins, Abstract, Nat Friedman and Daniel Gross, Valor Equity Partners, Eli Lilly Ventures, and Human Capital, among others.
The participation of Eli Lilly Ventures—the corporate venture arm of pharmaceutical major Eli Lilly & Company—is particularly noteworthy, suggesting strategic alignment and potential partnership opportunities between NewLimit and one of the world's largest drug manufacturers. The mix of dedicated venture firms, crossover investors, and corporate venture capital indicates NewLimit has achieved sufficient scale and technological maturation to attract diversified capital sources within the biotechnology investment ecosystem.
The funding syndicate reflects broad institutional confidence in NewLimit's business model and technology. Beyond lead investor Founders Fund, the round included new investors Thrive Capital, Greenoaks, and Quiet Capital. Returning investors participating in the round include Kleiner Perkins, Abstract, Nat Friedman and Daniel Gross, Valor Equity Partners, Eli Lilly Ventures, and Human Capital, among others.
The participation of Eli Lilly Ventures—the corporate venture arm of pharmaceutical major Eli Lilly & Company—is particularly noteworthy, suggesting strategic alignment and potential partnership opportunities between NewLimit and one of the world's largest drug manufacturers. The mix of dedicated venture firms, crossover investors, and corporate venture capital indicates NewLimit has achieved sufficient scale and technological maturation to attract diversified capital sources within the biotechnology investment ecosystem.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.